HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

New Horizon Health (6606.HK) - Far from Complete Reversal

Health And Happiness (H&H) (1112.HK) - High Bankruptcy Risk Together with Gloomy Prospects

Would the Cheap Versions of Oral COVID-19 Antiviral Bring New Opportunities for Chinese Companies?

WuXi AppTec (2359.HK/603259.CH)- Interesting Points to Ponder Behind 2021 Preliminary Financial Data

Oral COVID-19 Antivirals and the Impact on China

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

<ul>
<li>Benefiting from the opportunities brought to the healthcare industry by the COVID-19 pandemic in 2020, <a href="https://www.smartkarma.com/entities/yunkang-group" target="_blank" data-smartkarma-citation="entities:35631:1" rel="noopener">Yunkang Group (YK HK)</a> took a ride and ushered in a turning point in performance.</li>
<li>As the pandemic stabilizes and gets gradually under control, the revenue generated from COVID-19 tests may significantly decrease, which means Yunkang may return to net loss again in the future.</li>
<li>We currently haven’t seen any new growth point with high certainty. Therefore, we are conservative about Yunkang’s outlook.</li>
</ul>


Benefiting from the opportunities brought to the healthcare industry by the COVID-19 pandemic in 2020, Yunkang Group (YK HK) took a ride and ushered in a turning point in performance.
As the pandemic stabilizes and gets gradually under control, the revenue generated from COVID-19 tests may significantly decrease, which means Yunkang may return to net loss again in the future.
We currently haven’t seen any new growth point with high certainty. Therefore, we are conservative about Yunkang’s outlook.


Guangzhou Kingmed Diagnostics (603882 CH)

Pre-IPO Yunkang Group - Lack of New Growth Point